Floatz logo

Cixutumumab

Breast Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

209 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BBB
Tamoxifen
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB

View all 50 →

Same molecule, other indications

Cixutumumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative · Phase 2
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative · Phase 2
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →